Abstract
The Step-by-step clinical trial (NCT02906917) in basal insulin ± oral antidiabetic drugs treated people with type 2 diabetes (T2D) confirmed a similar glycemic effect for insulin degludec/insulin aspart (IDegAsp) versus basal+bolus insulin treatment (BB) of IGlar U100 + IAsp that was consistent over 38-weeks period with a significantly lower risk of nocturnal hypoglycemia. The aim of the present analysis was to assess the short-term cost-effectiveness of IDegAsp vs BB in Indian setting.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have